Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure

Gavazzi, Antonello; Marioni, R; Campana, Carlo; Montemartini, C

doi:10.1097/00004872-199407030-00012

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparative trial of quinapril versus captopril in patients with mild-to-moderate congestive heart failure suggested that treatment with 20 mg quinapril once a day was as effective as 100 mg captopril twice a day [ 93 ]. The results of this study are generally consistent with those of Acanfora et al [ 94 ] who showed quinapril was as effective as captopril in reducing signs and symptoms of congestive heart failure patients (New York Heart Association [NYHA] class II to III) and improving left ventricular function and exercise capacity.…”

Section: Quinaprilmentioning

confidence: 99%

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Balakumar

Jagadeesh

2015

Pathophysiology and Pharmacotherapy of Cardiovascular Disease

View full text Add to dashboard Cite

Drugs with diversifi ed structure and class target the RAAS cascade at various levels. Beginning with the inhibition of renin from the juxtaglomerular cells of the kidney, it extends to the blockade of formation and actions of its principal component, Ang II, and its effector, aldosterone and its synthesis. Although all of them are very effi cacious in combating overactivation of RAAS, ACE inhibitors and ARBs stand out in the armamentarium of RAAS inhibitors. All of them are effective in lowering blood pressure but differ from each other in potency, pharmacokinetic properties and additional pharmacologic actions that are contributed by their unique functional groups. Therapeutic uses of RAAS blockers stem from the dynamics of the complex intertwined downstream signaling molecules that interact to contribute beyond blood pressure control. Thus, some of the ACE inhibitors and ARBs are also indicated in the treatment of heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy in T2DM, reducing the risk of cardiovascular mortality, nonfatal myocardial infarction, and the risk of developing heart failure. Several studies have investigated the dual inhibition of the RAAS in hypertension and heart failure with an outcome of more adverse events without an increase in benefi t. While considering Ang II and aldosterone escape processes during ACE inhibitors and ARBs therapies, RAAS at the base level can be halted using aldosterone receptor antagonists for the management of hypertension and heart failure. InThe opinions expressed herein are those of GJ and do not necessarily refl ect those of the US Food and Drug Administration.

show abstract

Section: Quinaprilmentioning

confidence: 99%

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Balakumar

Jagadeesh

2015

Pathophysiology and Pharmacotherapy of Cardiovascular Disease

View full text Add to dashboard Cite

show abstract

“…Результаты мета-анализа рандомизированных клинических испытаний (РКИ) ингибиторов АПФ [1] и небольших исследований [2][3][4], в ходе которых непосредственно сравнивали разные ингибиторы АПФ, позволяли предположить, что применение разных ингибиторов АПФ сопровождается сходным снижением смертности. В то же время, результаты других сравнительных испытаний ингибиторов АПФ [5,6], а также обсервационных исследований свидетельствовали об обратном [7,8].…”

unclassified

Suppression of Renin-Angiotensin System to Prevent Complications of Cardiovascular Diseases: Current "Roles" Distribution From Clinical Pharmacologist’s Point of View

Gilyarevskiy¹,

Орлов²,

Голшмид³

et al. 2011

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Истина в науке. Не позволяйте фактам вводить вас в заблуждение. Закон Мерфи Введение В течение трех десятилетий после начала клинического применения ингибиторы ангиотензин-превращающего фермента (АПФ) наряду со статинами заняли одно из главных мест в профилактике и лечении осложнений сердечно-сосудистых заболеваний (ССЗ), представленных в сердечно-сосудистом континууме. Роль приема ингибиторов АПФ настолько очевидна, что приводить какие-либо доводы в пользу обоснованности их широкого использования в настоящее время нет необходимости. Несмотря на сходство эффектов блокаторов рецепторов ангиотензина II (БРА) и ингибиторов АПФ, именно последние остаются препаратами первого ряда для профилактики осложнений ССЗ среди средств, влияющих на ренинангиотензиновую систему. Выбор ингибитора АПФ в определенной клинической ситуации Как же подойти к выбору наиболее эффективного ингибитора АПФ при лечении конкретного больного? Можно предложить 2 подхода: 1) выбор препарата, обладающего наиболее приемлемыми физико-химическими свойствами для обеспечения клинического эффекта и защитного действия на сердце и сосуды; 2) вы-Сведения об авторах:

show abstract

Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis

Chitnis

Aparasu

Chen

et al. 2012

Research in Social and Administrative Pharmacy

View full text Add to dashboard Cite

Comparative trial of quinapril versus captopril in mild to moderate congestive heart failure

Cited by 7 publications

References 0 publications

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Suppression of Renin-Angiotensin System to Prevent Complications of Cardiovascular Diseases: Current "Roles" Distribution From Clinical Pharmacologist’s Point of View

Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: A multiple-propensity analysis

Contact Info

Product

Resources

About